DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Olmsted syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOlmsted syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for olmsted syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Olmsted syndrome is a rare congenital disorder characterised by symmetrical, destructive, inflammatory palmoplantar keratoderma with periorificial keratotic plaques, onychodystrophy, and variable leukokeratosis. Gain-of-function mutations in the TRPV3 gene are the most common cause, and mutations in different structural domains may lead to varying severity, suggesting a potential genotype-phenotype correlation. Two new related male patients were reported in 2007, one with the full-blown spectrum and the other with early signs, representing the third familial cases described. A female patient reported in 2005 had a haemangioma in addition to other features, and two unrelated female patients reported in 2009 presented with perioral hyperkeratosis and palmoplantar keratoderma; one had woolly hair and flexion contracture of a digit, the other had pseudoainhum, and neither had cardiac involvement.
A 63-year-old man with Olmsted syndrome causing severe pain and impairing quality of life since birth was treated with erlotinib 100 mg once daily. This led to a dramatic improvement in both pain and quality of life. Due to side-effects, the dose was reduced to 100 mg three times a week, which maintained efficacy with minimal side-effects. No other drug treatments are reported in these abstracts.
The 2024 review papers note that diagnosis is often challenging and delayed, and that recent genetic discoveries may inform future research and potential targeted therapies. The reviews underscore the need for a multidisciplinary approach but do not report any controlled trials or systematic treatment data.
What is still missing are controlled clinical trials, any formal dose-finding studies, patient stratification by TRPV3 mutation type, and long-term safety data for erlotinib or any other agent. No randomised evidence exists, and the single case report, while striking, cannot be generalised. Funding for multicentre trials and registries is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2007 · 22 citations
Olmsted syndrome in an Iranian family: report of two new cases.
AbstractOlmsted syndrome is a rare congenital entity characterized by combination of symmetrical, sharply-defined palmoplantar keratoderma with flexion deformities of the digits, periorificial keratosis, perianal involvement, onychodystrophy, and variable leukokeratosis. Herein, we report two new related male patients--the third familial cases of Olmsted syndrome--one with the full-blown spectrum of the syndrome, and the other with early signs and symptoms of the disorder.
Clinical and Experimental Dermatology · 2005 · 16 citations
Olmsted syndrome: report of a new case with unusual features
AbstractOlmsted syndrome is a rare disorder characterized by the combination of periorificial keratotic plaques and bilateral palmoplantar keratoderma. New associated features continue to be reported. Olmsted syndrome in a female patient is particularly rare, and we report such a case having a haemangioma in addition to other features of the syndrome.
Frontiers in Genetics · 2024 · 4 citations · open access
Pathogenesis and management of TRPV3-related Olmsted syndrome
AbstractOlmsted syndrome is characterized by symmetrically distributed, destructive, inflammatory palmoplantar keratoderma with periorificial keratotic plaques, most commonly due to gain-of-function mutations in the transient receptor potential vanilloid 3 (TRPV3) gene, which involves multiple pathological functions of the skin, such as hyperkeratosis, dermatitis, hair loss, itching, and pain. Recent studies suggest that mutations of TRPV3 located in different structural domains lead to cases of varying severity, suggesting a potential genotype-phenotype correlation resulting from TRPV3 gene mutations. This paper reviews the genetics and pathogenesis of Olmsted syndrome, as well as the potential management and treatment. This review will lay a foundation for further developing the individualized treatment for TRPV3-related Olmsted syndrome.
Clinical and Experimental Dermatology · 2024 · 2 citations
A case of Olmsted syndrome with dramatic response to erlotinib
AbstractA 63-year-old man with Olmsted syndrome, which was causing him severe pain and had been impairing his quality of life since birth, was treated with erlotinib 100 mg once daily. This led to a dramatic improvement in both his pain and quality of life. Owing to side-effects, the dose was reduced to 100 mg three times a week, which has maintained efficacy. Side-effects are now minimal.
International Journal of Research in Dermatology · 2024 · 0 citations · open access
Olmsted syndrome: clinical manifestations, genetic insights and therapeutic approaches in a rare keratoderma condition
AbstractOlmsted syndrome (OS) is a rare congenital disorder characterized by progressive, mutilating palmoplantar keratoderma, periorificial keratotic plaques, and severe pruritus. First described in 1927, OS presents with a myriad of clinical manifestations, making diagnosis challenging and often delayed. Recent advancements in genetic analysis have identified mutations in the TRPV3 gene as a primary etiological factor, offering new insights into the pathophysiology of the disease. This review aims to provide a comprehensive overview of OS, including its epidemiology, clinical features, genetic basis, and current therapeutic strategies. We also discuss the implications of recent genetic discoveries on future research and potential targeted therapies, underscoring the need for a multidisciplinary approach to manage this debilitating condition.
Indian Journal of Dermatology · 2009 · 0 citations · open access
Reflexiones a propósito de la Ley 26.485 y las perspectivas de género, la no discriminación y el discurso jurídico
AbstractOlmsted syndrome is an uncommon genetic disorder with symmetrical, diffuse, transgredient, mutilating palmoplantar keratoderma and periorificial hyperkeratosis. Olmsted syndrome in a female patient is particularly rare, and we report two unrelated female patients of Olmsted syndrome, who presented with perioral hyperkeratosis and palmoplantar keratoderma. One of our patients also had woolly hair from birth and flexion contracture of a digit, while the other had pseudoainhum. There was no cardiac involvement. Hence, the diagnosis of Olmsted syndrome was made.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
